We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genta Initiates new Clinical Trial of Tesetaxel, the Leading Oral Taxane in Clinical Development
News

Genta Initiates new Clinical Trial of Tesetaxel, the Leading Oral Taxane in Clinical Development

Genta Initiates new Clinical Trial of Tesetaxel, the Leading Oral Taxane in Clinical Development
News

Genta Initiates new Clinical Trial of Tesetaxel, the Leading Oral Taxane in Clinical Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genta Initiates new Clinical Trial of Tesetaxel, the Leading Oral Taxane in Clinical Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genta Incorporated has announced it has initiated a new clinical trial with tesetaxel, the latest addition to Genta’s oncology product portfolio. Unlike standard taxanes such as paclitaxel (Taxol®), which must be infused intravenously, tesetaxel is administered by mouth as a capsule.

The new study will examine the clinical pharmacology of the drug over a narrow dosing range around the established Phase 2 dose. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.

“Taxanes are the most widely used class of anticancer compounds,” commented Dr. Loretta M. Itri, Genta’s President, Pharmaceutical Development, and Chief Medical Officer.

Dr. Itri added, “Successful development of an oral taxane has been a research goal that has eluded many pharmaceutical companies. Tesetaxel has already been tested in more than 250 patients with various types of cancer in the U.S., Europe, and Japan. By eliminating serious hypersensitivity infusion reactions, as well as potentially reducing nerve damage and overcoming resistance to standard taxanes, tesetaxel may offer important new treatment options for patients with advanced cancer.”
Advertisement